Fate Therapeutics Announces Leadership Transition; Scott Wolchko To Retire As President And CEO, Bob Valamehr To Become President And CEO January 1, 2025
Fate Therapeutics Announces Leadership Transition; Scott Wolchko To Retire As President And CEO, Bob Valamehr To Become President And CEO January 1, 2025
Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025
Bob Valamehr博士MBA將於2025年1月1日擔任總裁兼首席執行官
Scott Wolchko To Retire as President and CEO after 10 years of Leadership in Pioneering iPSC-derived Cellular Immunotherapies
Scott Wolchko將在開拓性iPSC衍生細胞免疫療法領域領導10年後退休
SAN DIEGO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE) ("Fate Therapeutics" or the "Company"), a clinical-stage biopharmaceutical company dedicated to bringing first-in-class induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that Scott Wolchko, the Company's President and CEO, will retire effective December 31, 2024. Fate's current President of Research and Development (R&D), Bob Valamehr, Ph.D. MBA, will assume the role of President and CEO as of January 1, 2025. Fate Therapeutics will passionately continue its mission to develop novel off-the-shelf cellular immunotherapies to broadly treat patients in need.
聖地亞哥，2024年11月29日（納斯達克：FATE）（「Fate Therapeutics」或「公司」）——致力於爲患癌症和自身免疫性疾病患者帶來首創的誘導型多能幹細胞（iPSC）衍生細胞免疫治療方案的臨床階段生物製藥公司Fate Therapeutics, Inc.今天宣佈，該公司總裁兼首席執行官Scott Wolchko將於2024年12月31日生效退休。Fate現任研發總裁Bob Valamehr博士MBA將於2025年1月1日接任總裁兼首席執行官一職。Fate Therapeutics將激情地繼續其使命，開發新型的現貨細胞免疫治療方案，廣泛治療有需要的患者。
譯文內容由第三人軟體翻譯。
